Outpatient Autologous Stem Cell Transplant Can Be Safe for Multiple Myeloma, Lymphoma

Share this content:
Outpatient autologous HSCT can result in excellent outcomes in multiple myeloma and lymphoma.
Outpatient autologous HSCT can result in excellent outcomes in multiple myeloma and lymphoma.

With daily outpatient evaluation and aggressive supportive care, outpatient autologous hematopoietic stem cell transplantation (HSCT) can result in excellent outcomes in patients with multiple myeloma and lymphoma, a study published last month in the journal Bone Marrow Transplantation has shown.

Because autologous HSCT is being increasingly offered in the outpatient setting, researchers sought to evaluate the safety of outpatient autologous HSCT.

Researchers analyzed the outcome of 230 patients who underwent autologous HSCT on an inpatient basis compared with those who received it in the outpatient setting for multiple myeloma or lymphoma within a single transplant program at a cancer center day hospital.

Results showed that median time to neutrophil recovery was 10 days in the outpatient group versus 11 days in the inpatient group (P < 0.001) and the median time to platelet recovery was 19 and 20 days, respectively (P = 0.053).

RELATED: High Fracture Incidence Among Hematopoietic Stem Cell Recipients

Researchers found that grade 3-4 non-hematologic toxicities occurred in 29% of each group.

The study also showed that 2-year progression-free survival was 62% and 54% for the outpatient and inpatient groups, respectively (P = 0.155). For the outpatient cohort, 1- and 2-year overall survival was 97% and 83%, respectively, compared with 91% and 80%, respectively, in the inpatient group (P = 0.271).

Reference

  1. Graff TM, Singavi AK, Schmidt W, et al. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transpl. 2015. [Epub ahead of print]. doi: 10.1038/bmt.2015.46.

Editor's Note: A previous version of this article mistakenly referred to the 1- and 2- year overall survival rates of the outpatient cohort, the error has been corrected in this version.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters